LDN212854 Chemical Properties

Density 

1.33±0.1 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

DMSO: soluble1mg/mL, clear (warmed)

form 

powder

pka

8.79±0.10(Predicted)

color 

white to beige

InChIKey

BBDGBGOVJPEFBT-UHFFFAOYSA-N

CAS DataBase Reference

1432597-26-6

Safety Information

Hazard Codes 

Xn

Risk Statements 

22

WGK Germany 

3

LDN212854 Usage And Synthesis

Description

LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively.

In vitro

In myofibroblast C2C12 cells, LDN-212854 exhibits greater selectivity for BMP6-versus BMP4-induced osteogenic differentiation.

In vivo

LDN-212854 (6 mg/kg, i.p.) effectively neutralize ALK2 signaling in vivo, and potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.

Uses

5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline, contains the pyrazolo[1,5-a]pyrimidine scaffold, acting as a novel and selective bone morphogenetic protein receptor (BMP) inhibitors. It is a COVID19-related research product.

Biological Activity

ldn-212854 is a selective inhibitor of bone morphogenetic protein (bmp) signaling with ic50 value of 1.2nm [1].in the kinase assay, ldn-212854 shows inhibitory activities against caalk2 and caalk5 with ic50 values of 16nm and 2μm, respectively. it demonstrates that ldn-212854 is selective against bmp over tgf-β signaling. besides that, the inhibition of caalk2 caused by ldn-212854 is 6- and 10-fold more potent than that of caalk1 and caalk3, respectively. in c2c12 cells transfected with bmp receptors, ldn-212854 also exerts preferential inhibition against caalk2. furthermore, in a transgenic alk2q207d model of heterotopic ossification, treatment of ldn-212854 prevents the formation of heterotopic bone and preserves limb range of motion [1].

Biochem/physiol Actions

LDN-212854 is also known as 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline. LDN-212854 prevents heterotopic ossification in an inducible mutant ALK2 (activin receptor-like kinase 2).

References

[1] mohedas a h, xing x, armstrong k a, et al. development of an alk2-biased bmp type i receptor kinase inhibitor. acs chemical biology, 2013, 8(6): 1291-1302.

LDN212854(1432597-26-6)Related Product Information

• LDN-212320
• LDN-193189 HCl
• LDN-214117
• 5-[6-(4-Methoxyphenyl)pyrazolo[1,5-a]
• ALK5 inhibitor II
• SB525334
• LDN-193189
• K 02288
• AT9283